GSK Sees Promise in Antibody Therapy against Coronavirus Variants, Looking at Japan Rollout Too

David Brooks, Vice President, Global Medical Affairs, Otilimab and COVID Therapeutics With cases of coronavirus variants spiking across the world, GlaxoSmithKline sees promise in its antibody therapy developed with Vir Biotechnology, David Brooks, the company’s head of COVID-19 therapeutics, tells...read more